Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells 282 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 282 shares of Twist Bioscience stock in a transaction on Friday, December 20th. The stock was sold at an average price of $44.90, for a total transaction of $12,661.80. Following the completion of the transaction, the senior vice president now directly owns 133,433 shares of the company’s stock, valued at $5,991,141.70. The trade was a 0.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Paula Green also recently made the following trade(s):

• On Friday, December 6th, Paula Green sold 860 shares of Twist Bioscience stock. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00.
• On Monday, November 11th, Paula Green sold 1,347 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $64,656.00.
• On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total value of $246,147.40.
• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total value of $143,025.10.

Twist Bioscience Stock Up 0.7 %

Shares of Twist Bioscience stock traded up $0.33 during trading on Thursday, reaching $49.23. The company’s stock had a trading volume of 486,846 shares, compared to its average volume of 939,671. The company has a 50-day simple moving average of $45.51 and a two-hundred day simple moving average of $46.72. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -13.68 and a beta of 1.82.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors have recently added to or reduced their stakes in TWST. Caprock Group LLC increased its holdings in shares of Twist Bioscience by 2.9% during the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after acquiring an additional 220 shares in the last quarter. Signaturefd LLC grew its position in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the last quarter. Arizona State Retirement System increased its stake in Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after purchasing an additional 308 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Twist Bioscience by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after buying an additional 312 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Twist Bioscience by 2.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock worth $734,000 after buying an additional 363 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Barclays reduced their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Evercore ISI increased their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Leerink Partners raised their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Wolfe Research assumed coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, Scotiabank raised their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and an average price target of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.